Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 1, 2003, Pages 47-52

  Ni, Dan ^a   Ho, Dah H ^a   Vijjeswarapu, Mary ^a   Felix, Edward ^a   Rhea, P Robyn ^a   Newman, Robert A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acid metabolite; Antitumor agent; Homoharringtonine; Metabolism

Indexed keywords

2' HYDROXY 2' (ALPHA ACETIC ACID) 6' HYDROXY 6' METHYLHEPTANOYLCEPHALOTAXINE; CEPHALOTAXINE; DRUG METABOLITE; HOMOHARRINGTONINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN HL 60; CEPHALOTAXUS HARRINGTONIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MEDICINAL PLANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CEPHALOTAXUS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HARRINGTONINES; HL-60 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; MALE; MASS SPECTROMETRY; MICE;

EID: 0037735274     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2003.01066.x     Document Type: Article

References (16)

1. Powell RG, Weisleder D, Smith CR. Structure of cephalotaxine and related alkaloids. Tetrahedron Lett 46: 4081-4084, 1969.
2. Powell RG, Weisleder D, Smith CR. Antitumor alkaloids from Cephalotaxine harringtonia. Structure and activity. J Pharm Sci 61: 1227-1230, 1972.
3. Clinical Brochure. Homoharringtonine (NSC 141633). Bethesda, MD: Investigational Drug Branch. Cancer Therapy Evaluation Program. Division of Cancer Treatment, National Cancer Institute, August 1982.
4. Ohnuma T, Holland JF. Homoharringtonine as a new antileukemic agent. J Clin Oncol 3: 604-606, 1985.
5. Warrell RP, Coonley CJ, Gee TS. Homoharringtonine: An effective new drug for remission induction in refractory non-lymphoblastic leukemia. J Clin Oncol 3: 617-621, 1985.
6. Legha SS, Keating M, Picket S, Ajani J, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68: 1085-1091, 1984.
7. Kantarjian H, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: History, current research, and future directions. Cancer 92: 1591-1605, 2001.
8. Newman F, Meeks KN, Denine EP. Final phase II report of task I: Preclinical intravenous toxicity study of homoharringtonine (NSC 141633) in CDF mice and beagle dogs. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1981. Contract No. NO1-CM-17365.
9. Zhang Y, Yu H, Luo X, Zheng Y, Li W, Liu X, Yuan Y. Experimental studies on the toxicity of harringtonine and homoharringtonine. Chin Med J 92: 175-180, 1979.
10. Savaraj N, Lu K, Dimery I, Feun L, Burgess M, Keating M, Loo TL. Clinical pharmacology of homoharringtonine. Cancer Treat Rep 70: 1403-1407, 1986.
11. Lu K, Savaraj N, Feun LG, Guo Z, Umsawasdi T, Loo TL. Pharmacokinetics of homoharringtonine in dogs. Cancer Chemother Pharmacol 20: 139-142, 1988.
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-63, 1983.
13. Scudiero DA. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827-4883, 1988.
14. 50 and its error by means of logarithmic probit graph paper. Proc Soc Expt Biol Med 57: 261-264, 1944.
15. Cui YY, Wang ME. The metabolism of homoharringtonine by liver microsomes of rats and rabbits. Acta Pharmaceutica Sinica 26: 274-279, 1991.
16. Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer 82: 987-995, 1995.